Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

Texas MPN Workshop 2022 | Exciting updates in MF: novel targets and agents

Lucia Masarova • 26 Aug 2022
Texas MPN Workshop 2022
Myelofibrosis Myeloproliferative Neoplasms Imetelstat Navitoclax Parsaclisib Ruxolitinib

Lucia Masarova, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, shares some exciting updates and novel agents to look out for in myelofibrosis (MF), including navitoclax, parsaclisib, and imetelstat. This interview took place at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.

More from Lucia Masarova

Promising combination strategies being explored in myelofibrosis
3:27
Promising combination strategies being explored in myelofibrosis
Lucia Masarova • 22 Aug 2025
The most promising emerging therapies and developments in PV and ET
1:56
The most promising emerging therapies and developments in PV and ET
Lucia Masarova • 22 Aug 2025
The rationale for investigating T-regulatory cell therapy in myelofibrosis
2:24
The rationale for investigating T-regulatory cell therapy in myelofibrosis
Lucia Masarova • 22 Aug 2025
An update on BET inhibition for the treatment of myelofibrosis
2:34
An update on BET inhibition for the treatment of myelofibrosis
Lucia Masarova • 22 Aug 2025

Related Videos

Guidance for selecting between JAK inhibitors in the frontline and second-line setting for MF
1:26
Guidance for selecting between JAK inhibitors in the frontline and second-line setting for MF
Lucia Masarova • 6 Dec 2025
An overview of ongoing Phase III trials investigating novel treatment options for myelofibrosis
1:40
An overview of ongoing Phase III trials investigating novel treatment options for myelofibrosis
Lucia Masarova • 6 Dec 2025
The management of patients with ET or PV during pregnancy
3:32
The management of patients with ET or PV during pregnancy
Lucia Masarova • 7 Dec 2025
Preliminary analysis of the FEDORA trial: fedratinib plus ropeginterferon alfa-2b in myelofibrosis
2:37
Preliminary analysis of the FEDORA trial: fedratinib plus ropeginterferon alfa-2b in myelofibrosis
Lucia Masarova • 7 Dec 2025
The content of VJHemOnc is intended for healthcare professionals